INSM Strangle Strategy
INSM (Insmed Incorporated), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM (Insmed Incorporated) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $25.57B, a beta of 0.89 versus the broader market, a 52-week range of 64.85-212.75, average daily share volume of 2.6M, a public-listing history dating back to 2000, approximately 1K full-time employees. These structural characteristics shape how INSM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.89 places INSM roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on INSM?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current INSM snapshot
As of May 15, 2026, spot at $109.73, ATM IV 48.90%, IV rank 27.06%, expected move 14.02%. The strangle on INSM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on INSM specifically: INSM IV at 48.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a INSM strangle, with a market-implied 1-standard-deviation move of approximately 14.02% (roughly $15.38 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated INSM expiries trade a higher absolute premium for lower per-day decay. Position sizing on INSM should anchor to the underlying notional of $109.73 per share and to the trader's directional view on INSM stock.
INSM strangle setup
The INSM strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With INSM near $109.73, the first option leg uses a $115.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed INSM chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 INSM shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $115.00 | $4.55 |
| Buy 1 | Put | $105.00 | $4.20 |
INSM strangle risk and reward
- Net Premium / Debit
- -$875.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$875.00
- Breakeven(s)
- $96.25, $123.75
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
INSM strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on INSM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$9,624.00 |
| $24.27 | -77.9% | +$7,197.92 |
| $48.53 | -55.8% | +$4,771.84 |
| $72.79 | -33.7% | +$2,345.76 |
| $97.05 | -11.6% | -$80.32 |
| $121.31 | +10.6% | -$243.60 |
| $145.57 | +32.7% | +$2,182.48 |
| $169.84 | +54.8% | +$4,608.56 |
| $194.10 | +76.9% | +$7,034.64 |
| $218.36 | +99.0% | +$9,460.72 |
When traders use strangle on INSM
Strangles on INSM are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the INSM chain.
INSM thesis for this strangle
The market-implied 1-standard-deviation range for INSM extends from approximately $94.35 on the downside to $125.11 on the upside. A INSM long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current INSM IV rank near 27.06% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on INSM at 48.90%. As a Healthcare name, INSM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to INSM-specific events.
INSM strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. INSM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move INSM alongside the broader basket even when INSM-specific fundamentals are unchanged. Always rebuild the position from current INSM chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on INSM?
- A strangle on INSM is the strangle strategy applied to INSM (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With INSM stock trading near $109.73, the strikes shown on this page are snapped to the nearest listed INSM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are INSM strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the INSM strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 48.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$875.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a INSM strangle?
- The breakeven for the INSM strangle priced on this page is roughly $96.25 and $123.75 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current INSM market-implied 1-standard-deviation expected move is approximately 14.02%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on INSM?
- Strangles on INSM are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the INSM chain.
- How does current INSM implied volatility affect this strangle?
- INSM ATM IV is at 48.90% with IV rank near 27.06%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.